ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $338.38 million. The enterprise value is $143.37 million.
Important Dates
The last earnings date was Monday, May 5, 2025, after market close.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 71.09 million shares outstanding. The number of shares has increased by 23.91% in one year.
| Current Share Class | 71.09M |
| Shares Outstanding | 71.09M |
| Shares Change (YoY) | +23.91% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 77.28% |
| Float | 46.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.53 |
| P/TBV Ratio | 1.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.00, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.00 |
| Quick Ratio | 11.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.45% and return on invested capital (ROIC) is -32.34%.
| Return on Equity (ROE) | -48.45% |
| Return on Assets (ROA) | -30.87% |
| Return on Invested Capital (ROIC) | -32.34% |
| Return on Capital Employed (ROCE) | -65.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.16M |
| Employee Count | 115 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.40% in the last 52 weeks. The beta is 1.36, so ORIC's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -48.40% |
| 50-Day Moving Average | 5.87 |
| 200-Day Moving Average | 8.56 |
| Relative Strength Index (RSI) | 41.19 |
| Average Volume (20 Days) | 590,806 |
Short Selling Information
The latest short interest is 11.19 million, so 15.74% of the outstanding shares have been sold short.
| Short Interest | 11.19M |
| Short Previous Month | 13.26M |
| Short % of Shares Out | 15.74% |
| Short % of Float | 24.18% |
| Short Ratio (days to cover) | 13.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -146.62M |
| Pretax Income | -101.76M |
| Net Income | -132.86M |
| EBITDA | -145.48M |
| EBIT | -146.62M |
| Earnings Per Share (EPS) | -$1.88 |
Full Income StatementBalance Sheet
The company has $203.72 million in cash and $8.72 million in debt, giving a net cash position of $195.01 million or $2.74 per share.
| Cash & Cash Equivalents | 203.72M |
| Total Debt | 8.72M |
| Net Cash | 195.01M |
| Net Cash Per Share | $2.74 |
| Equity (Book Value) | 219.74M |
| Book Value Per Share | 3.09 |
| Working Capital | 193.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$115.01 million and capital expenditures -$1.36 million, giving a free cash flow of -$116.37 million.
| Operating Cash Flow | -115.01M |
| Capital Expenditures | -1.36M |
| Free Cash Flow | -116.37M |
| FCF Per Share | -$1.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |